Hypoglycemia in Type 2 Diabetes Patients Substituted with Insulin Degludec Aspart from Premixed Insulin Therapy: a Quasi Experimental Study

Authors

  • Komal Mumtaz Malik Department of Pharmacology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Sadia Zafar Pharmacy Department, Quaid-e-Azam University Islamabad
  • Shabana Ali Army Medical College, National University of Medical Sciences https://orcid.org/0000-0001-5684-3822
  • Mudassir Noor Department of Pharmacology, Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Noaman Ishaq Bakhtawar Amin Medical & Dental College, Multan Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i2.9745

Keywords:

Biphasic Insulin Aspart, Glycemic Control, Insulin Degludec Aspart, Type 2 Diabetes Mellitus

Abstract

Objective: To determine whether Insulin Degludec Aspart is associated with a reduced risk of hypoglycemia as compared to
premixed Insulin aspart therapy in type-2 diabetes mellitus patients.

Study Design: Quasi-experimental study

Place and Duration of Study: Department of Pharmacology, Army Medical College, National University of Medical Sciences,
Rawalpindi and Department of Medicine, Pak Emirates Military Hospital, Rawalpindi Pakistan, from Sep to Dec 2021.

Methodology: One hundred twenty participants with documented type 2 diabetes, taking premixed Insulin Aspart therapy,
were enrolled in the study. The participants were divided into two groups. Group-A participants were continued on Premixed
Insulin Aspart therapy, and Group-B participants were substituted with Insulin Degludec Aspart. The symptomatic
hypoglycemic episodes were recorded for 12 weeks as confirmed hypoglycemia, nocturnal hypoglycemia, and severe
hypoglycemia.

Results: Among the Premixed Insulin Aspart-Group, 49(81.6%) participants and in the Insulin Degludec Aspart-Group,
26(43.3%) participants reported 160 and 40 episodes of confirmed total hypoglycemia, respectively (p-value<0.001). 43(71.6%)
participants in the Premixed Insulin Aspart-Group and 11(18.3%) participants in the Insulin Degludec Aspart-Group reported
73 and 12 episodes of confirmed nocturnal hypoglycemia, respectively (p-value<0.001). No severe hypoglycemic episodes
were recorded in both groups after 12 weeks.

Conclusion: The use of Degludec Aspart is associated with a reduced incidence of hypoglycemia, offering improved treatment
compliance among the Pakistani population with type 2 diabetes.

Downloads

References

Fulcher G, Mehta R, Fita EG, Ekelund M, Bain SC. Efficacy and

Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly

Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3

Randomized Controlled BOOST Trials. Diabetes Ther 2019;

(1): 107-118. https://doi.org/10.1007/s13300-018-0531-0

Davies MJ, D'Alessio DA, Fradkin J. Management of

Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report

by the American Diabetes Association (ADA) and the European

Association for the Study of Diabetes (EASD). Diabetes Care

; 41(12): 2669-2701. https://doi.org/10.2337/dci18-0033

Dixit JV, Giri PA, Badgujar SY. 'Daily 2-only meals and exercise'

lifestyle modification for remission of type 2 diabetes mellitus: A

therapeutic approach. J Family Med Prim Care 2022; 11(9): 5700-

https://doi.org/ 10.4103/jfmpc.jfmpc_129_22

Lagani V, Chiarugi F, Thomson S. Development and validation

of risk assessment models for diabetes-related complications

based on the DCCT/EDIC data. J Diabetes Complications 2015;

(4): 479-487. https://doi.org/ 10.1016/j.jdiacomp.2015.03.001

Vamvini MT, Dushay JR, Abrahamson MJ. Virtually Better

Diabetes Care?. Clin Diabetes. 2019; 37(3): 284-286.

https://doi.org/10.2337/cd18-0052

Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G.

Efficacy and safety of patient-led versus physician-led titration

of basal insulin in patients with uncontrolled type 2 diabetes: a

meta-analysis of randomized controlled trials. BMJ Open

Diabetes Res Care 2020; 8(1): e001477.

https://doi.org/10.1136/bmjdrc-2020-001477

Haluzík M, Fulcher G, Pieber TR, Bardtrum L, Tutkunkardas D,

Rodbard HW, et al. The co-formulation of insulin degludec and

insulin aspart lowers fasting plasma glucose and rates of

confirmed and nocturnal hypoglycaemia, independent of

baseline glycated haemoglobin levels, disease duration or body

mass index: A pooled meta-analysis of phase III studies in

patients with type 2 diabetes. Diabetes Obes Metab 2018; 20(7):

-1592. https://doi.org/10.1111/dom.13261

Moon S, Chung HS, Kim YJ. Efficacy and Safety of Insulin

Degludec/Insulin Aspart Compared with a Conventional

Premixed Insulin or Basal Insulin: A Meta-Analysis. Metabolites

; 11(9): 639. https://doi.org/10.3390/metabo11090639

Kalra S, Atkin S, Cervera A. Multinational Consensus: Insulin

Initiation with Insulin Degludec/Aspart (IDegAsp) Adv Ther

; 35(7): 928-936. https://doi.org/10.1007/s12325-018-0712-2

Fujimoto K, Iwakura T, Aburaya M, Matsuoka N. Twice-daily

insulin degludec/insulin aspart effectively improved morning

and evening glucose levels and quality of life in patients

previously treated with premixed insulin: an observational

study. Diabetol Metab Syndr 2018; 10: 64.

https://doi.org/10.1186/s13098-018-0366-x

Özçelik S, Çelik M, Vural A, Aydın B, Özçelik M, Gozu H, et al.

Outcomes of transition from premixed and intensive insulin

therapies to insulin aspart/degludec co-formulation in type 2

diabetes mellitus: a real-world experience. Arch Med Sci 2020;

(1): 1-8. https://doi.org/10.5114/aoms.2020.93264

Cho KY, Nakamura A, Oba-Yamamoto C. Switching to OnceDaily Insulin Degludec/Insulin Aspart from Basal Insulin

Improves Postprandial Glycemia in Patients with Type 2

Diabetes Mellitus: Randomized Controlled Trial. Diabetes Metab

J 2020; 44(4): 532-541. https://doi.org/10.4093/dmj.2019.0093

Lane WS, Favaro E, Rathor N. A Randomized Trial Evaluating

the Efficacy and Safety of Fast-Acting Insulin Aspart Compared

With Insulin Aspart, Both in Combination With Insulin

Degludec With or Without Metformin, in Adults With Type 2

Diabetes (ONSET 9). Diabetes Care 2020; 43(8): 1710-1716.

https://doi.org/10.2337/dc19-2232

Haahr H, Fita EG, Heise T. A Review of Insulin

Degludec/Insulin Aspart: Pharmacokinetic and

Pharmacodynamic Properties and Their Implications in Clinical

Use. Clin Pharmacokinet 2017; 56(4): 339-354.

https://doi.org/10.1007/s40262-016-0455-7

Downloads

Published

29-04-2024

Issue

Section

Original Articles

How to Cite

1.
Malik KM, Zafar S, Ali S, Noor M, Ishaq N. Hypoglycemia in Type 2 Diabetes Patients Substituted with Insulin Degludec Aspart from Premixed Insulin Therapy: a Quasi Experimental Study. Pak Armed Forces Med J [Internet]. 2024 Apr. 29 [cited 2025 Apr. 6];74(2):473-7. Available from: https://pafmj.org/PAFMJ/article/view/9745